2.48

0.00% 0.00

After Hours: 2.50 0.02 +0.81%

C 4 Therapeutics Inc (CCCC)

Overview News Price History Option Chain Financials Discussions Forecast

C 4 Therapeutics Inc stock is traded at $2.48, with a volume of 5.97M. It is up +0.00% in the last 24 hours and up +10.22% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Previous Close:

$2.48

Open:

$2.44

24h Volume:

5.97M

Relative Volume:

3.10

Market Cap:

$176.50M

Revenue:

$20.76M

Net Income/Loss:

$-132.49M

P/E Ratio:

-0.9288

EPS:

-2.67

Net Cash Flow:

$-108.55M

1W Performance:

+4.64%

1M Performance:

+10.22%

6M Performance:

+56.96%

1Y Performance:

-54.99%

1-Day Range:

$2.44

$2.57

1-Week Range:

$2.17

$2.57

52-Week Range:

$1.085

$5.62

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name

C 4 Therapeutics Inc

Sector

Healthcare (1131)

Industry

Biotechnology (634)

Phone

(617) 231-0700

Address

490 ARSENAL WAY, WATERTOWN

Employee

110

Twitter

Next Earnings Date

2025-02-24

Latest SEC Filings

CCCC's Discussions on Twitter

Compare CCCC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CCCC C 4 Therapeutics Inc	2.48	226.78M	20.76M	-132.49M	-108.55M	-2.67
VRTX Vertex Pharmaceuticals Inc	434.19	106.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	681.72	68.81B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	452.74	58.35B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	889.89	53.55B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	377.47	36.43B	4.56B	-176.77M	225.30M	-1.7177

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-17-25	Initiated	Barclays	Overweight
Sep-15-25	Upgrade	Stephens	Equal-Weight → Overweight
Sep-04-25	Initiated	Guggenheim	Buy
Dec-19-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Equal-Weight
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral
Dec-13-23	Upgrade	Stifel	Hold → Buy
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Apr-28-22	Initiated	Credit Suisse	Underperform
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Mar-10-22	Initiated	JP Morgan	Overweight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Nov-23-21	Initiated	BofA Securities	Buy
Oct-14-21	Initiated	SVB Leerink	Mkt Perform
Sep-30-21	Initiated	Stifel	Hold
Jun-04-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Oct-28-20	Initiated	UBS	Buy
Oct-27-20	Initiated	BMO Capital Markets	Outperform
Oct-27-20	Initiated	Jefferies	Buy

View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

05:48 AM

Will earnings trigger a reversal in C4 Therapeutics Inc.Sell Signal & AI Enhanced Trade Execution Alerts - newser.com

05:48 AM

04:15 AM

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

04:15 AM

Nov 11, 2025

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times

Nov 11, 2025

C4 Therapeutics Inc. stock trend forecastMarket Activity Summary & Daily Technical Stock Forecast Reports - newser.com

Nov 11, 2025

Nov 10, 2025

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail

Nov 10, 2025

Is C4 Therapeutics Inc. stock positioned for digital transformationJobs Report & Growth Oriented Trading Recommendations - newser.com

Nov 10, 2025

Nov 09, 2025

Can trapped investors hope for a rebound in C4 Therapeutics Inc.Risk Management & Precise Buy Zone Tips - newser.com

Nov 09, 2025

Nov 07, 2025

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com

Nov 07, 2025

Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Nov 07, 2025

Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Nov 07, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 07, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Nov 07, 2025

Using economic indicators to assess C4 Therapeutics Inc. potential2025 Market WrapUp & Accurate Trade Setup Notifications - newser.com

Nov 07, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 07, 2025

Nov 06, 2025

C4 Therapeutics Reports Q3 2025 Financial Results - TipRanks

Nov 06, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Nov 06, 2025

C4 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener

Nov 06, 2025

C4 Therapeutics Raises Cash And Wins Wall Street’s Favor - Finimize

Nov 06, 2025